[{"orgOrder":0,"company":"Ethris","sponsor":"Neurimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurimmune and Ethris Enter Collaboration to Rapidly Develop Inhaled mRNA-based Antibody Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Ethris","sponsor":"Laureus Capital","pharmaFlowCategory":"D","amount":"$26.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Ethris","sponsor":"DIOSynVax","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Ethris","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla EU to Invest EUR 15 Million In Ethris, Initiating A Strategic Collaboration","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery"},{"orgOrder":0,"company":"Ethris","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Ethris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-induced Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Ethris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ethris","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Ethris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethris Announces Positive Initial Phase 1 Data for ETH47 mRNA Nasal Delivery","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Ethris
ETH47 is a lead mRNA candidate encoding interferon lambda (IFNλ). It is being evaluated in the early-stage clinical trial studies for the treatment of asthma.
The funding aims to support the company first-in-class mRNA-based product candidate ETH47, which is being evaluated in the early-stage clinical trial studies for the treatment of asthma.
ETH47 is a first-in-class, broadly protective antiviral candidate which is under phase 1 clinical development for the treatment and prophylaxis of viral asthma exacerbations.
MHRA approved company to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47 (induce a mucosal innate immune defense), in healthy participants for the treatment and prophylaxis of respiratory viral infections.
Under the terms of the agreement, Heqet will lead the development of ETH51, RNA-based therapeutics for heart attack and heart failure, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.
ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.
Ethris will design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs. This vaccine approach aims to provide protection from SARS-CoV-2 - the virus which causes COVID-19 disease.
The proceeds will advance the company’s lead programs ETH47 and ETH42, into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle delivery platforms and increase its manufacturing capabilities.
Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.